Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer. Methods Pubmed, Cochrane, Embase, and Web of Science were searched for articles published until 15 June 2022. The outcome m...
making decisions about how do you treat a patient with platinum-sensitive ovarian cancer in terms of the choice of chemotherapy, and also whether or not to use maintenance treatment. Joyce, do you want to just give us a few points about these two questions? DR. LIU: Yeah, so I t...
2856 ChinMedJ2oo9:122{23):2856—2860 Originalarticle Treatmentofplatinum—resistantrecurrentovariancancerusinga ‘‘predictivemoleculetargetedroutinechemotherapy’’system ZHAOXiao—dong,WEIFeng—hua,ZHANGYi,HEShu—rongandYANGLi Keywords:ovarianneoplasms;recurrence;chemotherapy;predictivemolecule Background Correctdru...
Background and aim of the work: to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine combination in patients who had recurrent platinum resistant ovarian cancer. Patients and method: twenty one patients with recurrent platinum resistant ovarian cancer were designated to receive vinorelbine...
According to him, patients should be classified into two groups based on these considerations including chemosensitive and chemoresistant.doi:10.3816/COC.2009.n.013J. Tate ThigpenElsevier Inc.Clinical Ovarian Cancer
In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC. 关键词: Humans Ovarian Neoplasms Neoplasm ...
ovarian cancer ORR: objective response rate PARP: poly(ADP-ribose) polymerase PARPi: PARP inhibitor PDS: primary debulking surgery PFI: platinum-free interval PFS: progression-free survival PR: partial response Pt-R: platinum-resistant Pt-S: platinum-sensitive RAP: rucaparib access...
OBJECTIVE: The aim of this study was to determine the potential benefit and complications of prolonged salvage and maintenance chemotherapy among patients with recurrent epithelial ovarian cancer who achieve response to salvage chemotherapy. METHODS: Patients with recurrent platinum-sensitive epithelial ovarian...
Trabectedin showed potential as a single-agent therapy for advanced, recurrent, platinum-sensitive ovarian cancerdoi:Trabectedin, therapeutic useOvarian-cancer, treatmentTrabectedin, therapeutic useGUJRAL ML.M L GUJRALInpharma
- 《Cancer Investigation》 被引量: 73发表: 2004年 A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. PURPOSE: A multicentric, phase II study to evaluate the efficacy and safety of the combination paclitaxel and oxaliplatin ...